NBIX - Neurocrine Biosciences Market Capitalization

Public company logo of Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences (NBIX) maintains an impeccable reputation in neuroscience, developing breakthrough therapies for severe brain pathologies. This price chart reflects a market capitalization of 16.77. The business model's revenues are based on the sale of high-cost licensed medications to clinics and insurance companies. Robust patent protection and FDA certifications block the expansion of new players into this niche.

NBIX (Neurocrine Biosciences, Inc.) Market Capitalization history from 07/04/2022 to 11/17/2026

NBIX (Neurocrine Biosciences, Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
Fundamental company analysis:NBIX (Neurocrine Biosciences Inc)
Product sample of neurocrine.com

The strategic partnership of Neurocrine Biosciences (NBIX) with pharmaceutical behemoths and the joint funding of research establish a foundation for long-term business sustainability. By analyzing the issuer's market capitalization, an investor sees the aggregate market value of all shares, which allows for the differentiation of fundamental asset value growth from short-term speculation and determines the company's fair scale within the current development cycle.

Key competitors

Market Capitalization BIIB (Biogen Idec)|Market Capitalization Regencell|AXSM - Market Value|ACAD - Market Capitalization|XENE: Market Capitalization|Market Capitalization VKTX|Market Value Supernus Pharmaceuticals|Market Capitalization CPRX (Catalyst Pharmaceuticals Inc)|Market Capitalization DNLI|HRMY - Market Value|biohavenpharma.com - Market Valuation|Market Capitalization Amylyx Pharmaceuticals Inc AMLX|TRVI - Market Value|Market Value PRAX (Praxis Corp)|Anavex (AVXL) - Market Value|Market Value CeriBell, Inc. (CBLL)|Market Value Prothena Corporation plc|Market Capitalization alector.com|Market Value Annexon, Inc. (ANNX)|Market Valuation Omeros OMER|Neurogene Therapeutics - Market Valuation|Market Value ACIU|voyagertherapeutics.com - Market Capitalization|Neumora (NMRA) - Market Valuation|SCLX: Market Capitalization|Market Capitalization Tevogen Bio Holdings, Inc. TVGN|Market Valuation ACOG|CGTX (Cognition Therapeutics, Inc.) - Market Value|Market Capitalization IKT|Market Capitalization Cassava (SAVA)|Market Value Assertio ASRT|Coya Therapeutics, Inc. (COYA) - Market Value|VTGN: Market Valuation|Market Value OVID (ovidrx.com)|ABOS: Market Capitalization|CRVO - Market Capitalization|ATHE (alteritytherapeutics.com) - Market Capitalization|Market Valuation clene.com (CLNN)|Market Value pepgen.com (PEPG)|JUNS (Jupiter Neurosciences, Inc.) - Market Value|Market Capitalization RLMD (relmada.com)|Market Capitalization Annovis Bio Inc (ANVS)|GRCE: Market Valuation|Market Capitalization Firefly Neuroscience Inc AIFF|KLTO: Market Capitalization|NeuroSense Therapeutics Ltd - Market Value|Market Valuation RVPH|Market Capitalization MTVA (MetaVia Inc)|Market Value NeurAxis Inc (NRXS)|Helius Medical Technologies Inc. - Market Capitalization|Market Capitalization PASG (Passage Bio Inc.)|Market Capitalization bionomics.com.au NEUP|Minerva Neurosciences Inc - Market Capitalization|ATHA - Market Capitalization|ADXN: Market Capitalization|Alzamend (ALZN) - Market Capitalization|CYCN (cyclerion.com) - Market Capitalization|Protagenic Therapeutics (PTIX) - Market Capitalization|Market Value pasitheaclinics.com (KTTA)|CRGT (Cortigent Inc) - Market Value|Market Capitalization ATXI (Avenue Therapeutics Inc)|Market Value BCLI|Cara Therapeutics Inc - Market Capitalization|Chromocell Therapeutics (CHRO) - Market Valuation|ELYM (Eliem Therapeutics Inc.) - Market Valuation|ITCI - Market Capitalization|Market Value Longboard Pharma|Market Capitalization MRNS (Marinus Pharma)|Market Value NKGen Biotech Inc (NKGN)|NRBO - Market Value|Market Capitalization SAGE (Sage Therapeutics Inc)|Synaptogenix Inc. (SNPX) - Market Value|TRVN: Market Valuation|Market Capitalization vigilneuro.com VIGL|WENA (Anew Medical Inc.) - Market Valuation|Market Valuation Cerevel Therapeutics